Aflibercept Intravitreous Injection
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Polypoidal Choroidal Vasculopathy (PCV)
Conditions
Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)
Trial Timeline
Jan 1, 2026 → Dec 31, 2027
NCT ID
NCT07365371About Aflibercept Intravitreous Injection
Aflibercept Intravitreous Injection is a approved stage product being developed by Bayer for Polypoidal Choroidal Vasculopathy (PCV). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07365371. Target conditions include Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD).
What happened to similar drugs?
4 of 6 similar drugs in Polypoidal Choroidal Vasculopathy (PCV) were approved
Approved (4) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
20
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07365371 | Approved | Recruiting |
Competing Products
9 competing products in Polypoidal Choroidal Vasculopathy (PCV)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zimura + Eylea | Astellas Pharma | Phase 2 | 27 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2 | 35 |
| Verteporfin Photodynamic Therapy + Ranibizumab | Novartis | Approved | 43 |
| Brolucizumab 6mg + Brolucizumab 6mg | Novartis | Phase 3 | 40 |
| Intravitreal aflibercept injection 2.0mg | Regeneron Pharmaceuticals | Approved | 43 |
| Rescue Intravitreal Aflibercept Injection | Regeneron Pharmaceuticals | Approved | 39 |
| aflibercept 8 mg | Bayer | Phase 3 | 44 |
| aflibercept | Bayer | Approved | 40 |
| ranibizumab intravitreal injection | Pacific Biosciences | Phase 1 | 19 |